< Back to previous page
Researcher
Steven Joniau
- Disciplines:Urology and nephrology
Affiliations
- Urogenital, Abdominal and Plastic Surgery (Division)
Member
From1 Jan 2019 → Today - Woman and Child (Division)
Member
From1 Apr 2013 → 31 Dec 2018
Projects
1 - 10 of 19
- Improvement of therapeutic management in patients with high-risk and oligorecurrent prostate cancerFrom1 Oct 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Development of treatment intensification strategies for high-risk prostate cancer based on clinicopathological and molecular modeling, with the aim of delivering precision medicine to the individual patient.From1 Oct 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- The role of stromal components in urothelial cancerFrom4 Oct 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- New insights in the genomic architecture and treatment of high risk and oligometastatic prostate cancerFrom10 Sep 2021 → 30 Sep 2022Funding: Own budget, for example: patrimony, inscription fees, gifts
- Metastasis-directed therapy in castration-refractory prostate cancer (MEDCARE)From24 Sep 2020 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Classical and non-classical actions of androgens and their receptorFrom1 Oct 2019 → 30 Sep 2023Funding: IOF - technology concept exploration, BOF - projects
- Fellowship: Optimization patient treatment pathway by combining genotypic and phenotypic data.From17 Dec 2018 → 16 Dec 2019Funding: Private funding of national origin - undefined
- Novel insights in the definition and treatment of high risk and oligometastatic prostate cancerFrom1 Oct 2018 → 18 Nov 2022Funding: FWO fellowships
- Traveling the prostate cancer timeline in chase of treatment paradigms Can we cure the incurable?From1 Aug 2017 → 1 Oct 2021Funding: Own budget, for example: patrimony, inscription fees, gifts
- Towards a better stratification of intermediate- and high-risk non-muscle-invasive bladder cancer patientsFrom1 Sep 2016 → 1 Sep 2020Funding: Own budget, for example: patrimony, inscription fees, gifts
Publications
1 - 10 of 541
- Discovery of a novel androgen receptor antagonist, MEL-6, with stereoselective activity and optimization of its metabolic stability.(2024)
Authors: Christine Helsen, Steven Joniau, Frank Claessens
Pages: 106476 - Which Patients with Prostate Cancer and Lymph Node Uptake at Preoperative Prostate-specific Membrane Antigen Positron Emission Tomography/Computerized Tomography Scan Are at a Higher Risk of Prostate-specific Antigen Persistence After Radical Prostatectomy? Identifying Indicators of Systemic Disease by Integrating Clinical, Magnetic Resonance Imaging, and Functional Imaging Parameters.(2024)
Authors: Alexander Giesen, Steven Joniau
Pages: 231 - 240 - Re: Abiraterone and Olaparib for Metastatic Castration-resistant Prostate Cancer.(2024)
Authors: Alexander Giesen, Frank Claessens, Steven Joniau
Pages: 396 - Salvage vesiculectomy for local prostate cancer recurrence: surgical technique and early post-operative outcomes(2024)
Authors: Alexander Giesen, Kato Rans, Charlien Berghen, Steven Joniau
- PSMA PET/CT and PET/MRI in primary staging of prostate cancer and its effect on patient management(2024)
Authors: Alexander Giesen, Steven Joniau, Koen Van Laere, Michel Koole, Christophe Deroose, Karolien Goffin
Pages: 31 - 54 - Impact of the Standardization of Penile Cancer Care on the Quality of Care, Outcomes, and Academic-driven Centralization in a Single eUROGEN Referral Center.(2024)
Authors: Dirk De Ridder, Anne-Sophie Van Rompuy, Herlinde Dumez, Gert De Meerleer, Karolien Goffin, Hendrik Van Poppel, Steven Joniau, Maarten Albersen
Pages: 57 - 65 - The Use of Soy Isoflavones in the Treatment of Prostate Cancer: A Focus on the Cellular Effects(2023)
Authors: Steven Joniau, Charlien Berghen, Kato Rans, Gert De Meerleer
- Predictors of Recurrence After Metastasis-directed Therapy in Oligorecurrent Prostate Cancer Following Radical Prostatectomy(2023)
Authors: Charlien Berghen, Steven Joniau, Gert De Meerleer
Pages: 582 - 589 - Identification of the Optimal Candidates for Nodal Staging with Extended Pelvic Lymph Node Dissection Among Prostate Cancer Patients Who Underwent Preoperative Prostate-specific Membrane Antigen Positron Emission Tomography. External Validation of the Memorial Sloan Kettering Cancer Center and Briganti Nomograms and Development of a Novel Tool(2023)
Authors: Alexander Giesen, Steven Joniau
Pages: 543 - 552 - Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants(2023)
Authors: Gert De Meerleer, Frank Claessens, Steven Joniau
Pages: 2065 - +